BioCentury
ARTICLE | Clinical News

QS-21 flu vaccine: Began Phase I trial

November 20, 2000 8:00 AM UTC

Aquila Biopharmaceuticals Inc. (AQLA), Framingham, Mass. Product: QS-21 flu vaccine Business: Infectious diseases Therapeutic category: Immune stimulation Target: Immune cells Description: Influenza...